Please ensure Javascript is enabled for purposes of website accessibility

The Rise of the Sterile Injectable Drug Market

The Rise of the Sterile Injectable Drug Market

The ever-increasing focus on animal health innovation has ignited the growing demand for sterile injectable drug development and manufacturing. Recent data indicates that biologics, which are predominantly manufactured under sterile conditions, make up nearly a third of all global animal health product sales1 and it is predicted that this proportion will substantially grow over the coming years.

This development has amplified the need for outsourced innovation in the animal health industry. Outsourcing product development allows animal health companies to tap into the expertise and resources of external organisations, including academic institutions, contract development and manufacturing organisations (CDMOs), and start-ups to develop new products and technologies. Additionally, outsourcing can help to reduce costs and speed up the development process, which is particularly important in an industry that is becoming continuously more competitive. As such, outsourcing innovation is likely to become an increasingly important strategy for animal health companies looking to stay ahead of the curve and deliver innovative solutions to meet the evolving needs of their customers.

It is Argenta’s mission to collaborate and partner with animal health companies from all sizes from all over the world to accelerate innovation from Molecule to Market.

Our Pharmaceutical Sciences teams are uniquely equipped to develop your molecule into commercialisable animal health products of the highest quality, on a global scale. With over 200 years of combined experience behind us, our team members have devoted their careers to advancing pharmaceutical product development.

Recently, Argenta invested in equipment to support the non-GMP development of sterile injectables. Our team in Lawrence, Kansas, USA, can assist you with solubility enhancement, the development of solutions, suspensions and freeze-dried formulations as well as aseptic processing and terminal sterilisation of pre-clinical test article (PTA) preparations. They can also help actualise sterile biologics, including monoclonal antibodies (mAbs), and other new chemical entities (NCEs). In addition, our team has extensive experience in and know-how of controlled-release microspheres and in situ thermosetting gels.

If you would like to discuss how our Pharmaceutical Sciences team in Lawrence can support your product development journey, please contact us here.

Pharmaceutical Sciences Capabilities at Lawrence, Kansas, USA:

  • Sterile injectables (including biologics such as monoclonal antibodies)
  • Controlled-release microspheres
  • In situ thermosetting gels
  • Soft chew matrices (tasty 'Treats to Treat')
  • Tablets
  • Capsules
  • Transdermal solutions

1. HealthforAnimals. Global Trends in the Animal Health Sector. 2022 Outlook. (accessed 25th April 2023)

Continue Reading